Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 16, 2022

BUY
$4.69 - $9.84 $345,380 - $724,637
73,642 New
73,642 $573,000
Q2 2021

Aug 19, 2021

SELL
$12.89 - $16.58 $575,306 - $739,998
-44,632 Closed
0 $0
Q1 2021

May 17, 2021

SELL
$14.0 - $20.72 $647,360 - $958,092
-46,240 Reduced 50.88%
44,632 $641,000
Q4 2020

Feb 16, 2021

BUY
$12.67 - $26.23 $479,673 - $993,041
37,859 Added 71.41%
90,872 $1.78 Million
Q3 2020

Nov 10, 2020

SELL
$11.92 - $15.87 $5,268 - $7,014
-442 Reduced 0.83%
53,013 $687,000
Q1 2020

May 15, 2020

BUY
$5.69 - $17.78 $304,158 - $950,429
53,455 New
53,455 $455,000

Others Institutions Holding ATRA

About Atara Biotherapeutics, Inc.


  • Ticker ATRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 94,362,304
  • Market Cap $1.08B
  • Description
  • Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...
More about ATRA
Track This Portfolio

Track Thrivent Financial For Lutherans Portfolio

Follow Thrivent Financial For Lutherans and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Thrivent Financial For Lutherans, based on Form 13F filings with the SEC.

News

Stay updated on Thrivent Financial For Lutherans with notifications on news.